In addition, the co-delivery of nanoparticle-mediated STAT3 siRNA and TLR7/8 agonist or TLR3 agonist enhanced expression of co-stimulatory CD40 and CD86 in DCs, and DCs-mediated anti-tumor immunity [71,72]. Here, STAT3 is linked to neoplasm.